US Precision Medicine Market

ID: MRFR/Pharma/13135-HCR
100 Pages
Vikita Thakur
Last Updated: May 04, 2026
US Precision Medicine Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Cardiology, Neurology, Rare Diseases, Infectious Diseases), By Technology (Genomics, Proteomics, Metabolomics, Microbiomics, Bioinformatics), By End Use (Pharmaceutical Companies, Healthcare Institutions, Research Organizations, Diagnostic Laboratories) and By Product (Diagnostic Tools, Therapeutics, Genetic Testing, Data Analytics Solutions) - Growth Outlook & Industry Forecast 2025 To 2035
US Precision Medicine Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)9.97%
2024 Market Size$ 7.83 Billion
2025 Market Size$ 8.61 Billion
2035 Market Size$ 22.27 Billion
Key Players
Illumina
Thermo Fisher Scientific
Roche
Abbott Laboratories
Qiagen
Bristol-Myers Squibb
Trends
  • Advancements in Genomic Technologies
  • Integration of Artificial Intelligence
  • Regulatory Support for Innovation
Opportunities
  • Supportive Reimbursement Policies
  • Increased Investment in Biotechnology
  • Growing Prevalence of Chronic Diseases
Summary Table of Contents Segmentation Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Application (USD Billion) | |
      1. 4.1.1 Oncology | |
      2. 4.1.2 Cardiology | |
      3. 4.1.3 Neurology | |
      4. 4.1.4 Rare Diseases | |
      5. 4.1.5 Infectious Diseases |
    2. 4.2 Healthcare, BY Technology (USD Billion) | |
      1. 4.2.1 Genomics | |
      2. 4.2.2 Proteomics | |
      3. 4.2.3 Metabolomics | |
      4. 4.2.4 Microbiomics | |
      5. 4.2.5 Bioinformatics |
    3. 4.3 Healthcare, BY End Use (USD Billion) | |
      1. 4.3.1 Pharmaceutical Companies | |
      2. 4.3.2 Healthcare Institutions | |
      3. 4.3.3 Research Organizations | |
      4. 4.3.4 Diagnostic Laboratories |
    4. 4.4 Healthcare, BY Product (USD Billion) | |
      1. 4.4.1 Diagnostic Tools | |
      2. 4.4.2 Therapeutics | |
      3. 4.4.3 Genetic Testing | |
      4. 4.4.4 Data Analytics Solutions 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Illumina (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Thermo Fisher Scientific (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Roche (CH) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Abbott Laboratories (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Qiagen (DE) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Bristol-Myers Squibb (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 GRAIL (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Foundation Medicine (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Novartis (CH) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 US MARKET ANALYSIS BY APPLICATION |
    6. 6.3 US MARKET ANALYSIS BY TECHNOLOGY |
    7. 6.4 US MARKET ANALYSIS BY END USE |
    8. 6.5 US MARKET ANALYSIS BY PRODUCT |
    9. 6.6 KEY BUYING CRITERIA OF HEALTHCARE |
    10. 6.7 RESEARCH PROCESS OF MRFR |
    11. 6.8 DRO ANALYSIS OF HEALTHCARE |
    12. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    13. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    14. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE |
    15. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
    16. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
    17. 6.14 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE) |
    18. 6.15 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion) |
    19. 6.16 HEALTHCARE, BY END USE, 2024 (% SHARE) |
    20. 6.17 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion) |
    21. 6.18 HEALTHCARE, BY PRODUCT, 2024 (% SHARE) |
    22. 6.19 HEALTHCARE, BY PRODUCT, 2024 TO 2035 (USD Billion) |
    23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    24. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    25. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY PRODUCT, 2025-2035 (USD Billion) |
    26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.3.1 |
    27. 7.4 ACQUISITION/PARTNERSHIP | |

US Precision Medicine Market Segmentation

US Precision Medicine Market By Application (USD Billion, 2025-2035)

  • Oncology
  • Cardiology
  • Neurology
  • Rare Diseases
  • Infectious Diseases

US Precision Medicine Market By US Precision Medicine Market (USD Billion, 2025-2035)

  • Genomics
  • Proteomics
  • Metabolomics
  • Microbiomics
  • Bioinformatics

US Precision Medicine Market By End Use (USD Billion, 2025-2035)

  • US Precision Medicine Market Companies
  • US Precision Medicine Market Institutions
  • Research Organizations
  • Diagnostic Laboratories

US Precision Medicine Market By Product (USD Billion, 2025-2035)

  • Diagnostic Tools
  • Therapeutics
  • Genetic Testing
  • Data Analytics Solutions

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.